LLY·Healthcare·Pharma
Eli Lilly Foundayo Soars +4.6% as GLP-1 Pill Bets Grow
Can Eli Lilly Foundayo and the Centessa deal push Lilly’s GLP-1 dominance into an even more powerful multi-drug growth story?
Pharma
LLY·Healthcare·Pharma
NVO·Healthcare·Pharma
Novo Nordisk Wegovy Strategy +2.9% Rally After 70% Slide
Can the aggressive Novo Nordisk Wegovy Strategy subscription push really reverse a 70% stock slide and close the gap to…
ABBV·Healthcare·Dividend Aristocrats
AbbVie Dermatology Data Boom at AAD 2026 Shocks Investors
Can AbbVie’s latest dermatology data at AAD 2026 really secure its post-Humira growth story in immunology?
LLY·Healthcare·Pharma
Eli Lilly GLP-1 Strategy Boom and Revenue Shock
Can Eli Lilly’s GLP-1 boom keep powering the stock as regulation, lawsuits and ETF concentration risks close in?
PFE·Healthcare·Pharma
Pfizer Lyme vaccine 70% efficacy Shock as PFE slips
Can the Pfizer Lyme vaccine’s >70% efficacy data revive sentiment around PFE just as investors write off its post-COVID growth…
LLY·Healthcare·Pharma
Eli Lilly Retatrutide Boom: Triple-Agonist Trial Shock
Can Eli Lilly Retatrutide’s powerful Phase 3 diabetes data reignite confidence in the GLP-1 boom despite rising competitive and pricing…
LLY·Healthcare·Pharma
Eli Lilly Forecast Warning after HSBC’s bearish reset
Is the latest bearish Eli Lilly Forecast a rare buying opportunity or the start of a painful valuation reset in…
JNJ·Healthcare·Dividend Aristocrats
Johnson & Johnson FDA approval ICOTYDE Boom Explained
Can Johnson & Johnson’s FDA approval of ICOTYDE really shift the psoriasis market enough to move a $575 billion healthcare…
NVO·Healthcare·Pharma
Novo Nordisk GLP-1 competition Warning with new pill rival
Can Novo Nordisk defend its GLP-1 dominance as a potent oral rival emerges and a bold US telehealth deal reshapes…
NVO·Healthcare·Pharma
Novo Nordisk FDA warning: Safety shock and WHO funding pivot
Can the Novo Nordisk FDA warning derail the GLP-1 boom just as a new WHO partnership reshapes the company’s global…